Literature DB >> 22712267

[Oral combined hormonal contraception containing nomegestrol acetate and 17beta-oestradiol--the statement of Polish Gynecological Society Experts Group].

Romuald Debski, Jan Kotarski, Tomasz Paszkowski, Leszek Pawelczyk, Ryszard Poreba, Violetta Skrzypulec-Plinta, Jacek Tomaszewski.   

Abstract

Nomegestrol acetate (NOMAC) combined with E2 (Zoely) is a monophasic oral contraceptive (OC) which safety and efficacy was confirmed in a number of level I evidence clinical trials. Zoely is highly effective OC, especially in overweight and obese patients, with good cycle control, safe and well tolerated. NOMAC/E2 combination causes no or minimal weight gain and is characterized by minimal influence on bone mineral density or blood pressure and presence of acne. Moreover lipids profile, carbohydrates metabolism, haemostasis and endocrine glands functioning were not affected. High tolerance and acceptance of NOMAC/E2 combination by women, low adverse event profile, fast recovery of ovarian activity and ovulation is a reasonable treatment tool in everyday practice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22712267

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  1 in total

Review 1.  Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings.

Authors:  Małgorzata Bińkowska; Artur Jakimiuk; Tomasz Paszkowski; Leszek Pawelczyk; Violetta Skrzypulec-Plinta
Journal:  Prz Menopauzalny       Date:  2022-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.